This site is intended for health professionals only

Wednesday 19 June 2019
Share |

Topic: *** Editor's Pick

June 18, 2019
Using immuno-positron emission tomography to image monoclonal antibodies directed against specific innate immune cell markers, investigators were able to effectively assess IBD in murine models
Inflammation in inflammatory bowel disease (IBD) can be quickly and precisely diagnosed using a new type of nuclear medicine scan, according to research published in the June issue of The Journal of Nuclear Medicine.
 
June 18, 2019
This approval is based on data from the Phase III SOLO-1 trial, which showed that Lynparza, after a median follow-up of 40.7 months, lowered the risk of disease progression or death by 70% than with placebo
AstraZeneca and MSD have announced that the European Commission (EC) has approved Lynparza (olaparib) as a 1st-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer.
 
The licensed indication is as a maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of 1st-line platinum-based chemotherapy.
June 18, 2019
The research has focused on different types of macrophages, and how they work when bacteria are present
There is no precise cure for Crohn's disease and causes are believed to vary. But one indicator of the condition - an abnormal reaction of the immune system to certain bacteria in the intestines - has had new light shed on it thanks to scientists at the University of Plymouth.1
 
June 16, 2019
Study also reveals venous thromboembolism and epilepsy as potential novel comorbidities
A study has shown increased rates of type I diabetes and inflammatory bowel disease (IBD) in patients that go on to develop rheumatoid arthritis (RA).1 
 
Results of the study demonstrate that the RA group reported significantly more cases of inflammatory bowel disease (1.9% vs. 0.5%, p<0.001) and type I diabetes (1.3% vs. 0.4%, p=0.01) versus controls.1
 
June 15, 2019
Initial pilot data support the use of new neurostimulation treatment in a larger study in patients who have failed current standard of care
The results of a study suggest that electro stimulation of the vagus nerve could provide a novel treatment approach for patients with rheumatoid arthritis.1 
 
This is a really exciting development. For many patients suffering from rheumatoid arthritis, current treatments don’t work, or aren’t tolerated,” said Professor Thomas Dörner, Chairperson of the Scientific Programme Committee, EULAR. 
 
June 14, 2019
In the European Union alone, an extra one million employees could be in work each day if early interventions were more widely accessible for people with rheumatic and musculoskeletal diseases (RMDs)
EULAR has launched the Time2Work campaign to raise awareness of the impact rheumatic and musculoskeletal diseases (RMDs) have, not only on individuals, but wider society, productivity and our economies and what can be done to improve this situation.
 
Affecting one quarter of the EU population (120 million), RMDs are the biggest cause of sick leave and premature retirement due to physical disability. As one of the main causes of physical disability, RMDs contribute considerably to loss of productivity in the workplace.
June 14, 2019
Over half of patients and rheumatologists report diagnosis within six weeks as the most problematic standard of care
The results of a large pan-European survey presented at EULAR 2019 investigated significant gaps in rheumatoid arthritis care across 16 patient-centred Standards of Care (SoC) in rheumatoid arthritis.1  
 
June 14, 2019
Huge impact of pain and sleep on mental health raises questions about the level of care offered to patients
A survey has highlighted the significant impact of rheumatic and musculoskeletal diseases (RMDs) on mental health and a worrying lack of psychological care.1
 
June 13, 2019
A collaboration between hospitals and pharmacies in Cheshire and Merseyside has saved the NHS £11 million – and improved patient care
Pharmacies in Cheshire and Merseyside in the UK are being notified by their local hospital when a patient is discharged who might need help understanding changes to their medicines following their stay.
 
June 13, 2019
ApoB:A1 ratio and metabolomic lipoprotein signatures identified as new biomarkers for cardiovascular risk in juvenile SLE patients
The results of a study presented at EULAR 2019 identify ApoB:A1 ratio and metabolomic lipoprotein signatures as potential  biomarkers for cardiovascular risk in patients with  juvenile-onset systemic lupus erythematosus (JSLE).1
 
In depth metabolomics was used to investigate dyslipidaemia and cardiovascular risk in a cohort of patients with  JSLE. Unbiased hierarchical clustering stratified patients by metabolomic profile and revealed three distinct groups.
 
June 13, 2019
Study includes data from over 8000 people with psoriatic arthritis from four Nordic countries
The results of a study presented EULAR 2019 suggest that overall cancer risk is not linked to tumour necrosis factor inhibitor (TNFi) use in psoriatic arthritis.
 
June 13, 2019
Pixantrone has been available to patients since 2012 following a conditional approval in Europe
Servier has announced that the European Commission (EC) has approved the conversion of the conditional approval of Pixuvri® (pixantrone) into a standard marketing authorisation as a single agent for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma.
 
June 13, 2019
Study reports no vaccine infections in children given live-attenuated booster vaccine while on immune suppressing therapies
A study presented at EULAR 2019, jointly organised with the Paediatric Rheumatology Society (PReS), demonstrate no vaccine infections, and no disease flare, in the 234 rheumatic patients who received live-attenuated booster vaccination while taking immune suppressing therapies.1
 
June 12, 2019
Cardiovascular health and physical activity levels of prostate cancer patients improve following successful interventions by community pharmacies, new research in the British Medical Journal reports
In the first study of its kind, researchers from the University of Surrey, funded by the Movember Foundation in partnership with Prostate Cancer UK, developed and tested the feasibility of community pharmacies delivering programmes to improve levels of physical activity and diet of men with prostate cancer and those who have successfully completed treatment for the disease. 
 
June 12, 2019
Decision based on data from Phase III head-to-head study stopped early due to an overall survival efficacy benefit versus sunitinib, a current standard of care

Bristol-Myers Squibb has announced that the Scottish Medicines Consortium (SMC) has decided to fund the combination of Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for use within NHS Scotland as a first-line treatment option for an advanced form of the most common type of kidney cancer, renal cell carcinoma (RCC), specifically in previously-untreated patients who are considered of intermediate- and poor-prognostic risk.

June 11, 2019
A robust diagnosis is important to ensure the correct management is implemented and unnecessary food exclusion is avoided as there may be adverse nutritional consequences, especially if a major food group, such as milk, wheat or fruits/vegetables are excluded
Food allergy in adults is usually mediated by IgE antibodies, with one or more immediate typical allergic symptoms (flushing, hives, itching, swelling, vomiting, diarrhoea, difficulty breathing) to trigger foods.1
 
June 10, 2019
Oral semaglutide is an investigational once-daily oral glucagon-like peptide-1 receptor agonist
Findings presented from two Phase IIIa clinical trials evaluated oral semaglutide 14mg vs Jardiance® (empagliflozin 25mg) in PIONEER 2 and oral semaglutide 14mg versus Victoza® (liraglutide 1.8mg) in PIONEER 4 over 52 weeks in adults with type 2 diabetes. 
 
Data from both trials were presented at the American Diabetes Association (ADA) 79th Scientific Sessions. 
 
June 10, 2019
An upsurge in demand for proton beam therapy was predicted as the centenary of the discovery of the proton was celebrated at a major scientific conference
Proton beam therapy, an innovative form of radiotherapy that delivers cancer treatment in a more targeted manner, has recently arrived in the UK through the Rutherford Cancer Centres and an NHS facility. 
 
As the number of patients treated with this precision therapy grows, there is a debate about the benefits that this innovative treatment can bring.
 
June 7, 2019
Experts from Norway found that the risk of paediatric coeliac disease was 8% lower per 10g increase in fibre intake during pregnancy
High fibre intake during pregnancy is linked with a decreased risk of coeliac disease in children, new research presented at the 52nd Annual Meeting of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) has shown.1 
 
June 6, 2019
Scientists have found that young children with severe eczema infected with Staphylococcus aureus are at a higher risk of developing a food allergy
In a study published in the Journal of Allergy and Clinical Immunology, scientists from King's College London have found that young children with severe eczema infected with Staphylococcus aureus (SA) bacterium, are at a higher risk of developing a food allergy.1
 
Staphylococcus aureus (SA) is found in the nose and the skin of healthy individuals; however, SA is more common in sufferers of eczema, especially severe eczema.
 
June 6, 2019
The results support a robust set of existing data demonstrating the sustained efficacy, safety, and tolerability of continuous ibrutinib treatment in patients with CLL
Janssen has announced long-term follow-up results from two pivotal Phase III studies of Imbruvica® (ibrutinib) in patients with chronic lymphocytic leukaemia (CLL), a type of non-Hodgkin lymphoma and the most common form of leukaemia in adults.1 
 
June 6, 2019
In the Phase III POLYP 1 and POLYP 2 studies, omalizumab met both co-primary endpoints and key secondary endpoints in adults with chronic rhinosinusitis with nasal polyps with inadequate response to intranasal corticosteroids
Novartis has announced positive topline data from two Phase III, multicentre studies evaluating omalizumab (Xolair®) for the treatment of adults with chronic rhinosinusitis with nasal polyps (CRSwNP) who have not adequately responded to standard-of-care (intranasal corticosteroids). 
 
Omalizumab, an injectable biologic treatment designed to target and block immunoglobulin E (IgE), met both co-primary endpoints and key secondary endpoints across both POLYP 1 and POLYP 2 Phase III trials.
June 6, 2019
The risk of pneumonia was highest among those using strong opioids, such as oxycodone or fentanyl, but the risk was also increased among those using buprenorphine, tramadol or codeine
Opioid analgesics were associated with a 30% increase in the risk of pneumonia in persons with Alzheimer’s disease, a recent study from the University of Eastern Finland shows. 
 
The risk was most pronounced in the first two months of use. This is the first study to investigate the association between opioids and pneumonia in this population. The results were published in the Journal of Alzheimer’s Disease.1
 
June 6, 2019
Although most people with chronic constipation do not visit a doctor, it is still diagnosed in more than one million GP consultations and 63,000 hospital admissions in the UK every year; the way it is detected, however, varies considerably
Research by King's College London, published in the American Journal of Gastroenterology,1 finds that the public's perception of constipation differs drastically from that of doctors' and from the formal diagnosis guidelines.
 
Researchers also identified six key sets of symptoms common to both that in the future could form the basis of a new medical definition for constipation.